By Manas Mishra and Michael Erman (Reuters) -Johnson & Johnson on Tuesday rescinded its forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world. The company had previously predicted as much as $3.5 billion in 2022 sales from the single-dose vaccine, but demand has withered. Still, the company reported strong results for its medical devices business and raised its dividend, driving shares up around 3%. Use of the shot has been weak in high-income countries, hurt by …